{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:56:46Z","timestamp":1790114206032,"version":"4.0.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","jocn-journal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jocn.2025.111062","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T10:15:00Z","timestamp":1738145700000},"page":"111062","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["2-Hydroxyglutarate magnetic resonance spectroscopy for preoperative IDH molecular profiling \u2013 A review of the literature and real-world clinical translation in a busy neurosurgical neuro-oncology unit"],"prefix":"10.1016","volume":"133","author":[{"given":"Frances Anne","family":"McHugh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Luton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Parkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Newey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chungo","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Kastelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Horsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Back","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Drummond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2025.111062_b0005","doi-asserted-by":"crossref","unstructured":"Weller M et al. European Association for Neuro-Oncology (EANO) Task Force on Gliomas. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 2017 Jun;18(6):e315-e329. doi: 10.1016\/S1470-2045(17)30194-8. Epub 2017 May 5. Erratum in: Lancet Oncol. 2017 Nov;18(11):e642. PMID: 28483413.","DOI":"10.1016\/S1470-2045(17)30194-8"},{"key":"10.1016\/j.jocn.2025.111062_b0010","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"Weller","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jocn.2025.111062_b0015","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/bpa.12457","article-title":"cIMPACT-NOW (the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy): a new initiative in advancing nervous system tumor classification","volume":"27","author":"Louis","year":"2017","journal-title":"Brain Pathol"},{"key":"10.1016\/j.jocn.2025.111062_b0020","doi-asserted-by":"crossref","first-page":"74","DOI":"10.14791\/btrt.2019.7.e43","article-title":"The Korean Society for Neuro-Oncology (KSNO) guideline for WHO grade II cerebral gliomas in adults: version 2019.01","volume":"7","author":"Kim","year":"2019","journal-title":"Brain Tumor Res Treat"},{"key":"10.1016\/j.jocn.2025.111062_b0025","doi-asserted-by":"crossref","unstructured":"Martin J van den Bent, Pim J French, Daniel Brat, Joerg C Tonn, Mehdi Touat, Benjamin M Ellingson, Robert J Young, Johan Pallud, Andreas von Deimling, Felix Sahm, Dominique Figarella Branger, Raymond Y Huang, Michael Weller, Ingo K Mellinghoff, Tim F Cloughsey, Jason T Huse, Kenneth Aldape, Guido Reifenberger, Gilbert Youssef, Philipp Karschnia, Houtan Noushmehr, Katherine B Peters, Francois Ducray, Matthias Preusser, Patrick Y Wen, The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?,Neuro-Oncology, 26(10) 2024, pp. 1805\u20131822. https:\/\/doi.org\/10.1093\/neuonc\/noae107.","DOI":"10.1093\/neuonc\/noae107"},{"key":"10.1016\/j.jocn.2025.111062_b0030","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1158\/1078-0432.CCR-09-2902","article-title":"IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group","volume":"16","author":"van den Bent","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jocn.2025.111062_b0035","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.jocn.2025.111062_b0040","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"Yan","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2025.111062_b0045","doi-asserted-by":"crossref","unstructured":"van den Bent MJ, Tesileanu CMS, Wick W, Sanson M, Brandes AA, Clement PM, Erridge S, Vogelbaum MA, Nowak AK, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Rogers L, Taal W, Rud\u00e0 R, Weller M, McBain C, Reijneveld J, Enting RH, Caparrotti F, Lesimple T, Clenton S, Gijtenbeek A, Lim E, Herrlinger U, Hau P, Dhermain F, de Heer I, Aldape K, Jenkins RB, Dubbink HJ, Kros JM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, French P, Baumert BG. Adjuvant and concurrent temozolomide for 1p\/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2021 Jun;22(6):813-823. doi: 10.1016\/S1470-2045(21)00090-5. Epub 2021 May 14. PMID: 34000245; PMCID: PMC8191233.","DOI":"10.1016\/S1470-2045(21)00090-5"},{"key":"10.1016\/j.jocn.2025.111062_b0050","doi-asserted-by":"crossref","unstructured":"Patel SH, Bansal AG, Young EB, Batchala PP, Patrie JT, Lopes MB, Jain R, Fadul CE, Schiff D. Extent of Surgical Resection in Lower-Grade Gliomas: Differential Impact Based on Molecular Subtype. AJNR Am J Neuroradiol. 2019 Jul;40(7):1149-1155. doi: 10.3174\/ajnr.A6102. Epub 2019 Jun 27. PMID: 31248860; PMCID: PMC7048539.","DOI":"10.3174\/ajnr.A6102"},{"issue":"7","key":"10.1016\/j.jocn.2025.111062_b0055","doi-asserted-by":"crossref","first-page":"5289","DOI":"10.1007\/s00330-020-07467-4","article-title":"The T2-FLAIR Mismatch Sign as a Predictor of IDH-Mutant, 1p\/19q-Noncodeleted Lower-Grade Gliomas: A Systematic Review and Diagnostic Meta-Analysis","volume":"31","author":"Park","year":"2021","journal-title":"Eur Radiol"},{"key":"10.1016\/j.jocn.2025.111062_b0060","doi-asserted-by":"crossref","unstructured":"Choi C, Raisanen JM, Ganji SK, Zhang S, McNeil SS, An Z, Madan A, Hatanpaa KJ, Vemireddy V, Sheppard CA, Oliver D, Hulsey KM, Tiwari V, Mashimo T, Battiste J, Barnett S, Madden CJ, Patel TR, Pan E, Malloy CR, Mickey BE, Bachoo RM, Maher EA. Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH-Mutant Glioma. J Clin Oncol. 2016 Nov 20;34(33):4030-4039. doi: 10.1200\/JCO.2016.67.1222. Epub 2016 Oct 31. PMID: 28248126; PMCID: PMC5477829.","DOI":"10.1200\/JCO.2016.67.1222"},{"issue":"4","key":"10.1016\/j.jocn.2025.111062_b0065","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/jmri.25221","article-title":"MR spectroscopy for in vivo assessment of the oncometabolite 2-hydroxyglutarate and its effects on cellular metabolism in human brain gliomas at 9.4T","volume":"44","author":"Bisdas","year":"2016","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.jocn.2025.111062_b0070","article-title":"Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy","volume":"4(116):116ra4","author":"Andronesi","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jocn.2025.111062_b0075","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s10334-021-00989-y","article-title":"Diagnostic performance of edited 2HG MR spectroscopy of central glioma in the clinical environment","volume":"35","author":"Juskani\u010d","year":"2022","journal-title":"Magn Reson Mater Phy"},{"issue":"2","key":"10.1016\/j.jocn.2025.111062_b0080","doi-asserted-by":"crossref","first-page":"E2","DOI":"10.3171\/2012.12.FOCUS12355","article-title":"From genomics to the clinic: biological and translational insights of mutant IDH1\/2 in glioma","volume":"34","author":"Dunn","year":"2013","journal-title":"Neurosurg Focus"},{"key":"10.1016\/j.jocn.2025.111062_b0085","doi-asserted-by":"crossref","first-page":"16238","DOI":"10.1038\/srep16238","article-title":"IDH mutation status is associated with a distinct hypoxia\/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma","volume":"5","author":"Kickingereder","year":"2015","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.jocn.2025.111062_b0090","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/RCT.0000000000000705","article-title":"2-Hydroxyglutarate detection by short echo time magnetic resonance spectroscopy in routine imaging study of brain glioma at 3.0 T","volume":"42","author":"Crisi","year":"2018","journal-title":"J Comput Assist Tomogr"},{"issue":"1","key":"10.1016\/j.jocn.2025.111062_b0095","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/0008-5472.CAN-15-0934","article-title":"Noninvasive quantification of 2-hydroxyglutarate in human gliomas with IDH1 and IDH2 mutations","volume":"76","author":"Emir","year":"2016","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.jocn.2025.111062_b0100","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nm.2682","article-title":"2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas","volume":"18","author":"Choi","year":"2012","journal-title":"Nat Med"},{"issue":"18","key":"10.1016\/j.jocn.2025.111062_b0105","doi-asserted-by":"crossref","first-page":"4453","DOI":"10.3390\/cancers15184453","article-title":"Non-Invasive Assessment of Isocitrate Dehydrogenase-Mutant Gliomas Using Optimized Proton Magnetic Resonance Spectroscopy on a Routine Clinical 3-Tesla MRI","volume":"15","author":"de Godoy","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.jocn.2025.111062_b0110","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1093\/neuonc\/noy113","article-title":"2-Hydroxyglutarate MR spectroscopy for prediction of isocitrate dehydrogenase mutant glioma: a systemic review and meta-analysis using individual patient data","volume":"20","author":"Suh","year":"2018","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.jocn.2025.111062_b0115","doi-asserted-by":"crossref","unstructured":"Antonio Di Ieva, John S. Magnussen, Jeffery McIntosh, Michael J. Mulcahy, Margery Pardey, Changho Choi, Magnetic Resonance Spectroscopic Assessment of Isocitrate Dehydrogenase Status inGliomas: The New Frontiers of Spectrobiopsy in Neurodiagnostics, World Neurosurgery, Volume 133, 2020, Pages e421-e427, ISSN 1878-8750, https:\/\/doi.org\/10.1016\/j.wneu.2019.09.040.","DOI":"10.1016\/j.wneu.2019.09.040"},{"issue":"7","key":"10.1016\/j.jocn.2025.111062_b0120","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/neuonc\/nox214","article-title":"Highly specific determination of IDH status using edited in vivo magnetic resonance spectroscopy","volume":"20","author":"Branzoli","year":"2018","journal-title":"Neuro Oncol"},{"issue":"20","key":"10.1016\/j.jocn.2025.111062_b0125","doi-asserted-by":"crossref","first-page":"6078","DOI":"10.1158\/1078-0432.CCR-17-0560","article-title":"T2-FLAIR Mismatch, an Imaging Biomarker for IDH and 1p\/19q Status in Lower-grade Gliomas: A TCGA\/TCIA Project","volume":"23","author":"Patel","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.jocn.2025.111062_b0130","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1093\/neuonc\/noy048","article-title":"The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p\/19q-intact lower-grade glioma: a validation study","volume":"20","author":"Broen","year":"2018","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.jocn.2025.111062_b0135","doi-asserted-by":"crossref","unstructured":"Juratli TA, Tummala SS, Riedl A, Daubner D, Hennig S, Penson T, Zolal A, Thiede C, Schackert G, Krex D, Miller JJ, Cahill DP. Radiographic assessment of contrast enhancement and T2\/FLAIR mismatch sign in lower grade gliomas: correlation with molecular groups. J Neurooncol. 2019 Jan;141(2):327-335. doi: 10.1007\/s11060-018-03034-6. Epub 2018 Dec 7. PMID: 30536195; PMCID: PMC6924170.","DOI":"10.1007\/s11060-018-03034-6"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586825000347?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586825000347?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T21:28:21Z","timestamp":1740086901000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586825000347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":27,"alternative-id":["S0967586825000347"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2025.111062","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2-Hydroxyglutarate magnetic resonance spectroscopy for preoperative IDH molecular profiling \u2013 A review of the literature and real-world clinical translation in a busy neurosurgical neuro-oncology unit","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2025.111062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111062"}}